Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3330500 | 0.81 | ALDH1A1 (0.45) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL3330505 | 0.81 | ALDH1A1 (0.45) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL5185989 | 0.79 | PKM (0.40) | ALDH1A1KDM4EKMT2AMAPTHCAR3 | |
| SCHEMBL5894013 | 0.79 | ALDH1A1 (0.50) | ALDH1A1AGTR1KDM4EMEN1KMT2A | |
| SCHEMBL2343250 | 0.78 | ALDH1A1 (0.38) | ALDH1A1KMT2AHTTCYP1A2 | |
| SCHEMBL492480 | 0.77 | CYP1A2 (0.47) | ALDH1A1MEN1KMT2AMAPTGAA | |
| SCHEMBL492479 | 0.77 | CYP1A2 (0.47) | ALDH1A1MEN1KMT2AMAPTGAA | |
| SCHEMBL4035324 | 0.77 | ALDH1A1 (0.60) | ALDH1A1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL4715562 | 0.77 | L3MBTL1 (0.41) | ALDH1A1MEN1KMT2AMAPTGAA | |
| SCHEMBL16485936 | 0.76 | ALDH1A1 (0.64) | ALDH1A1MEN1KMT2AMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6815439-B2 | PYRROLO(2,3-B)PYRIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2004-11-09 | — | — | US | disclosed |
| US-20040072836-A1 | Substituted aza-oxindole derivatives | HARRIS PHILIP ANTHONY (US) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072836-A1 | Substituted aza-oxindole derivatives | CCNI, AZI2, CDKN1A | ALDH1A1 1625/4885AGTR1 1670/4885KDM4E 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.